Synonym
GF-001001-00; GF 001001-00; GF001001-00; M-5120; M5120; M 5120; T-3912; T 3912; T3912; GF-00100100; GF00100100; GF 00100100; Ozenoxacin; Xepi.
IUPAC/Chemical Name
1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
InChi Key
XPIJWUTXQAGSLK-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
SMILES Code
O=C(C1=CN(C2CC2)C3=C(C=CC(C4=CC(C)=C(NC)N=C4)=C3C)C1=O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Ozenoxacin is a nonfluorinated quinolone antibacterial, which shows potent activities against the main microorganisms isolated from skin and soft tissue infections.
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
3.9 |
10.81 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
363.42
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Koulenti D, Xu E, Mok IYS, Song A, Karageorgopoulos DE, Armaganidis A, Lipman J, Tsiodras S. Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms. 2019 Aug 18;7(8). pii: E270. doi: 10.3390/microorganisms7080270. Review. PubMed PMID: 31426596; PubMed Central PMCID: PMC6723731.
2: Schachner L, Andriessen A, Bhatia N, Grada A, Patele D. Topical Ozenoxacin Cream 1% for Impetigo: A Review. J Drugs Dermatol. 2019 Jul 1;18(7):655-661. Review. PubMed PMID: 31334625.
3: Clinical Review Report: Ozenoxacin 1% Cream (Ozanex): (Ferrer Internacional, S.A.): Indication: The topical treatment of impetigo in patients aged two months and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct. Available from http://www.ncbi.nlm.nih.gov/books/NBK539436/ PubMed PMID: 30942991.
4: Pharmacoeconomic Review Report: Ozenoxacin 1% Cream (Ozanex): (Ferrer Internacional, S.A.): Indication: The topical treatment of impetigo in patients aged two months and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct. Available from http://www.ncbi.nlm.nih.gov/books/NBK539347/ PubMed PMID: 30942989.
5: CADTH Canadian Drug Expert Committee Recommendation: Ozenoxacin 1% Cream (Ozanex — Ferrer Internacional, S.A.): Indication: The topical treatment of impetigo in patients aged two months and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK539227/ PubMed PMID: 30933450.
6: Vila J, Hebert AA, Torrelo A, López Y, Tato M, García-Castillo M, Cantón R. Ozenoxacin: a review of preclinical and clinical efficacy. Expert Rev Anti Infect Ther. 2019 Mar;17(3):159-168. doi: 10.1080/14787210.2019.1573671. Epub 2019 Feb 11. Review. PubMed PMID: 30686133.
7: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500961/ PubMed PMID: 30000020.
8: Wren C, Bell E, Eiland LS. Ozenoxacin: A Novel Topical Quinolone for Impetigo. Ann Pharmacother. 2018 Dec;52(12):1233-1237. doi: 10.1177/1060028018786510. Epub 2018 Jul 2. Review. PubMed PMID: 29962213.
9: Morimoto H, Kikukawa Y, Murakami N. Pharmacological profiles and clinical effects of ozenoxacin lotion for the treatments of acne vulgaris and superficial infection of the skin. Nihon Yakurigaku Zasshi. 2016 Jul;148(1):39-45. doi: 10.1254/fpj.148.39. Review. Japanese. PubMed PMID: 27430678.
10: Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014 Aug 15;90(4):229-35. Review. PubMed PMID: 25250996.
